Treatment should only be continued if there is a beneficial metabolic response (reduction of at least 11 mmol/mol [1%] in HbA1c and weight loss of at least 3% of initial body weight at 6 months)
However, coverage for the OSA indication varies by plansome MA plans have added Zepbound for OSA to their formularies while others have not
What to watch for: Even though the body is GLP-1-adapted, the GIP receptor component is new
For example, the UK Summary of Product Characteristics (SmPC) for Wegovy (semaglutide 2.4 mg) includes a precautionary note in Section 4.4 advising healthcare professionals to monitor patients for suicidal ideation and behaviour, particularly those with a history of psychiatric disorders
Losing muscle accelerates your metabolic rate decline, makes future weight regain faster and harder to reverse, and affects your strength, your energy, and your functional capacity for the next 20 years
Eli Lilly, a competitor of Novo Nordisks, anticipates its oral GLP-1 pill will receive FDA approval by the second quarter of 2026